In one paragraphTrial report in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Maria Antonia EspinosaPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0009-0006-2018-4734 Lindsey SefriedPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Jose VillamarinPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Lizeth CifuentesPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-7865-2947 Thomas FredrickPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-2906-1574 Diego AnazcoPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-1829-7001 Sima FansaPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Jamie FriendPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Thomas M RieckHealthy Living Program, Integrative Medicine and Health, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-5668-5454 Michael CamilleriPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-6472-7514 Maria D Hurtado AndradePrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-2322-7334 Matthew M ClarkPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-3887-4419 Donald D HensrudPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-6980-2245 Andres AcostaPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Funding
Phenotype-Tailored Lifestyle intervention for Obesity: A Randomized TrialR01DK139028 · NIDDK · MAYO CLINIC ROCHESTER · PI Andres J Acosta · 2024 to 2026
$2.0MMechanisms of Enteroendocrine L-Cell Dysfunction and Bile Adaptations to Weight LossK23DK114460 · NIDDK · MAYO CLINIC ROCHESTER · PI ACOSTA, ANDRES J · 2018 to 2022
$980kDairy Management N/AMayo Clinic Foundation N/ANIDDK NIH HHS K23 DK114460NIDDK NIH HHS R01 DK139028NIH HHS 5K23DK114460-22NIH HHS 5R01DK139028-25
6 · The paper itselfAbstract
BACKGROUND/
objectivesA 12-week trial demonstrated that phenotype-tailored lifestyle intervention (PLI) was associated with greater weight loss than standard lifestyle intervention (SLI); however, differences in dietary patterns between groups were not examined.
methodsThis secondary analysis evaluated caloric and macronutrient intake at 12 weeks in adults with obesity (BMI ≥ 30 kg/m
resultsGroups were compared at 12 weeks adjusting for baseline values. PLI was associated with lower total energy intake than SLI (1273 ± 182 vs. 1894 ± 176 kcal/day;
conclusionsPLI was associated with lower energy intake, mainly due to reduced carbohydrate and fat intake, and a higher relative contribution of protein, consistent with phenotype-based recommendations rather than macronutrient prescriptions. These findings suggest a potential role for personalized dietary approaches in obesity management. However, the non-randomized design does not allow causal inferences.
Indexed as
Energy IntakeLife StyleNutrientsObesityAdultEmotional EatingEnergy MetabolismFemaleHumansMaleMiddle AgedPhenotypeSatiationWeight Lossdietary intakelifestyle interventionmacronutrientsobesityphenotypesprecision medicine
Identifiers
PMID42884609
PMCPMC13666677
What OpenQuestion holds
Textmetadata
Read underepoch 390